648414-75-9

Upstream product

• 300856-44-4 (R)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-5-(4-benzyloxy-phenylamino)-pentanoic acid tert-butyl ester 
• 648411-32-9 (S)-4-Benzyl-3-{2-[(R)-1-(4-benzyloxy-phenyl)-2-oxo-pyrrolidin-3-yl]-acetyl}-oxazolidin-2-one 
• 300856-46-6 [(R)-1-(4-Benzyloxy-phenyl)-2-oxo-pyrrolidin-3-yl]-acetic acid 
• 179533-67-6 (R)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)hex-5-enoate 
• 648414-71-5 (S)-4-Benzyl-3-{2-[(R)-1-(4-benzyloxy-phenyl)-2-oxo-pyrrolidin-3-yl]-propionyl}-oxazolidin-2-one 
• 300856-45-5 [1-(4-benzyloxy-phenyl)-2-oxo-pyrrolidin-3-yl]-acetic acid tert-butyl ester 
• 300856-43-3 (R)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-5-oxo-pentanoic acid tert-butyl ester 

Downstream Products

• 648414-76-0 (S)-4-Benzyl-3-(2-{(R)-1-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-3-yl}-propionyl)-oxazolidin-2-one 

Relevant academic research and scientific papers

Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE)

New inhibitors of tumor necrosis factor-α converting enzyme (TACE) were discovered using an N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamide scaffold. The series was found to be potent in a porcine TACE (pTACE) assay with IC50s typically below 5 nM.